IP : Crescendo Biologics - Secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours
24 Jul 2023 $32 million additional capital raised, supported by all major existing investors and new investor Kreos Capital ...
Source: marketscreener.com